TRVI – trevi therapeutics, inc. (US:NASDAQ)

News

Trevi Therapeutics: Late-Stage Transition Meets Execution Risk [Seeking Alpha]
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Trevi Therapeutics launches $150M public stock offering [Seeking Alpha]
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com